Professional Documents
Culture Documents
CONT. CANCER
VACCINE BASICS
sources:
the
human
genome
project:
Cancer Vaccines
submitted by:
oreta, Herrera, dy
a brief background for
s
or
f d o
k ing
o m a
lo t
o r h en
a f
e d ib le
le . W us
n s b ro
o pe p on s si ce d
t e s p o a n a n
c r c
r oje c t is
in es of cell ies
P c e d
m e roje v ac e nc lthy stu ot
n o s p d u e a e n
i q h es if
Ge Th li ze s e a h
a n c h.
o n a
fi rs t
e n . “T
re d s are
r le
Hu
m
s ea p ers th e t w e
s i b u nd h ich
he ic re o f d be p o s
in
h
f
w
T if t h e s a o
ie nt ep b lis i s on a de o nt st
c r c o
sc co
n p u p a
e
m lls m
e ts o m e r c e s ,
th ticis s , c
s
w
c e r t ion
l
ne ell el an u ta
ge r c
or
c
ll
c m
o m t a fi c
tum e tu tha e ci
e s e d sp r.
th m o f o
n fir d s tum
co s an a ch
u e
tho e to
n iqu
u
A fe
wy
pro ears
vide late
con d r, a
tain c om Ger
i p e man
the n g lling star
bod cop tup
y ies e v id call
to ’s im of t enc ed
see m u he s e BioN
harb k out n e e m th at Tec
, at syst utat a
orin t e m io n v h
g a t s a
beg
an a them ck, an o pr
o d
cou
ld
ccin
e
l . d d uce c a t
in c arg In estr T ce alyz
olla e te Dec o y a lls p e
(MIT bor st o e m ll rime
atio f th
Tec nw e va ber 2 can
c e d
and hno it ccin 0 17, r
the logy h the e in c B ioN
cell
s
site targ Rev biot a Tec
s ar et is iew ech nce h
oun at le , 20 gian r pati
d th ast 19) t Ge ents
e gl 10 t . T he t nen ,
obe o 560 rial tech
. can is ong ,”
cer oing
pati
ents
at
h are
e n tec ing
G en s ign
an d d e ke
h m a
T ec to
B io N a n d u e s iz ed
h
Bot ng c h niq u stom ly.
i g te c u ick
a t n q
cre a c turi n a lly a nd t i on
f s o y a
man
u per h e apl the cre g a
e th c se m in
e s b o c a u rf o r r,
th e s b e “p e m o
a c cin e d ed lv e s
’s
tu
A ,
v n e n v o n t N
h is is
c in ei p atie it s D o
T
e v ac th e ly z ing tio nt
of th y on nd ana informa ch a
io p s g a h a t w hi
b n ci n
in g t
ft e r s to
u e sh a ee d
seq e n ru
n s it e
t h i s n
s pi tal
th tio d, h o
and roduc d u c e
o th e ie w ,
e p p ro re d t R ev
th e i s live ology
c i n d e
vac p t ly e c hn
e p rom IT T
b (M
r,”
afte .
0 1 9)
2
how is it useful?
cancer vaccines
Vaccines are created for the purpose of helping
the body to combat diseases. They function by
training the immune system to familiarize itself to
harmful substances so it may be able to
recognize then destroy it. There are two
categories for cancer vaccines (1) prevention
vaccines and (2) treatment vaccines.
cancer prevention
The U.S. Food and Drug Administration has
already approved 2 types of cancer prevention
vaccines. The first is the HPV vaccine which
helps protect one from the human papillomavirus
(HPV). The human papillomavirus (HPV) if long-
lasting could be a cause for certain types of
cancer. This HPV vaccine aims to stop (1) genital
warts, (2) anal cancer, (3) cervical cancer, (4)
vaginal cancer, and (5) vulvar cancer. HPV could
also be a cause for other cancers that the FDA
has not approved a vaccine for. One of which is
oral cancer. However, there is a vaccine for
Hepatitis B. This vaccine will help in the
prevention of the hepatitis B virus infection. The
HBV has long term detrimental effects that could
even cause liver cancer. However, there is still a
need to consult your personal doctor or health
team regarding whether or not you actually need
these vaccinations.
cancer treatment
Therapeutic vaccines unlike cancer prevention
vaccines are used for immunotherapy. These
vaccines function is to amplify an individual’s
natural defenses against cancer. These vaccines
are used to treat people who have already been
diagnosed to have cancer. The purposes of the
vaccine are to (1) terminate tumors, (2) prevent
tumors from spreading, (3) block the cancer from
coming back, and (4) shatter any cancer cells after
treatments have ended. The creation of these
cancer vaccines are important because
“conventional chemotherapies take a heavy toll on
healthy cells and aren’t always effective against
tumors,” (MIT Technology Review, 2019).
let's simplify
(a description of the science behind it, made easy.)
cancer vaccine b
“To create an
individuali
asics:
vaccine, resea zed cancer
rchers must
cancer-specific identify
peptides called
neoantigens, the
n use a cell-, pro
nucleic acid–ba tein-, or
sed platform to
those neoantige deliver
ns to patients to
the immune sys prime
tem to attack th
Antigen-presenti e tumor.
ng cells su
dendritic cells ch as
(purple) interna
cancer-specific lize the
peptides (brigh
selected for a t green)
personalized c
vaccine and d ancer
isplay them o
surface with n their
the help of
histocompatibilit major
y complex
proteins. This trig (MHC)
gers T cells (blu
receptors that b e) with
ind those neoan
differentiate into tigens to
effector, or killer,
(green) that T cells
mobilize an
reaction agains immune
t cancer cells (o
(Hundal & Mardis range).”
, 2019).